---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-285671"
form_type: "8-K"
ticker: "BNTC"
cik: "0001808898"
company_name: "Benitec Biopharma Inc."
filed_at: "2023-11-30T23:59:59+00:00"
generated_at: "2026-06-07T19:57:21.858715+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Benitec dosed first subject in Phase 1b/2a trial of BB-301 for OPMD dysphagia

## Summary
- BB-301 is a gene therapy candidate using Silence and Replace ddRNAi platform for Oculopharyngeal Muscular Dystrophy (OPMD).
- OPMD affects ~15,000 patients in US, Canada, Western Europe, and Israel; no approved therapies currently exist.
- Interim safety and efficacy data from the 52-week study expected in mid-2024.
- 19 subjects in the ongoing OPMD Natural History study are eligible to roll over into the BB-301 treatment study.

## SEC filing metadata
- accession: 0001193125-23-285671
- form_type: 8-K
- ticker: BNTC
- cik: 0001808898
- company_name: Benitec Biopharma Inc.
- filed_at: 2023-11-30T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1808898/000119312523285671/0001193125-23-285671-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1808898/000119312523285671/d401028d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-285671
- JSON: https://secwatch.observer/filing/0001193125-23-285671.json
- Plain text: https://secwatch.observer/filing/0001193125-23-285671.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.